Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, China.
Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, China.
Med Hypotheses. 2021 May;150:110568. doi: 10.1016/j.mehy.2021.110568. Epub 2021 Mar 23.
Our hypothesis proposes that activating κ-opioid receptors (KORs) may inhibit the progression of breast cancer and improve patient prognosis. Consequently, KORs may become a promising therapeutic target for breast cancer. Activating KORs induces not only analgesic efficacy comparable to μ-opioid receptors but also shows a promising antitumor effect and with fewer opioid-induced adverse effects. Based on present studies and our bioinformatics analysis of KORs, we propose that KORs can function as a tumor suppressor by inhibiting angiogenesis in human breast cancer; therefore, analgesics that mainly activate KORs would be more suitable for breast cancer patients.
我们的假设提出，激活 κ 阿片受体（KOR）可能会抑制乳腺癌的进展并改善患者的预后。因此，KOR 可能成为治疗乳腺癌的有前途的靶点。激活 KOR 不仅会产生与 μ 阿片受体相当的镇痛效果，而且还显示出有前途的抗肿瘤作用，并且阿片类药物引起的不良反应较少。基于目前的研究和我们对 KOR 的生物信息学分析，我们提出 KOR 可以通过抑制人乳腺癌中的血管生成来发挥肿瘤抑制作用；因此，主要激活 KOR 的镇痛药将更适合乳腺癌患者。
